CN-122011094-A - Retinoic aldehyde dehydrogenase activating peptide and application thereof in prevention and treatment of radiotherapy intestinal side reaction

Abstract

The invention discloses application of three euphausia superba-derived retinaldehyde dehydrogenase activation peptides in preventing or treating radiotherapy intestinal side reactions, and belongs to the technical field of bioactive peptides. The number of the euphausia superba-derived retinoid dehydrogenase-activating peptides is 3, and the amino acid sequences of the euphausia superba-derived retinoid dehydrogenase-activating peptides are respectively shown as SEQ ID NO. 1-3. The application of the euphausia superba-derived retinoid dehydrogenase-activating peptide in preventing or treating radiotherapy intestinal side-effects. The invention utilizes high-resolution mass spectrum to identify 3 potential retinol dehydrogenase activated peptides from antarctic krill protein peptide sequences, and utilizes animal experiments to verify the effect of the retinol dehydrogenase activated peptides in preventing or treating radiotherapy intestinal side effects. The results show that the 3 small molecular peptides can improve weight loss caused by radiation and intestinal structure damage, thereby repairing intestinal mucosa barrier and improving side effect of radiotherapy intestinal tract.

Inventors

• ZHONG FENG
• JIANG SUISUI
• GAO TIANLIN
• Yao sai

Assignees

• 青岛大学

Dates

Publication Date

20260512

Application Date

20260304

Claims (5)

1. 1. A retinaldehyde dehydrogenase activated peptide is characterized in that the amino acid sequence is FEEF, and is shown as SEQ ID NO. 1.
2. 2. A retinaldehyde dehydrogenase activated peptide is characterized in that the amino acid sequence is FGREE, and is shown as SEQ ID NO. 2.
3. 3. A retinaldehyde dehydrogenase activated peptide is characterized in that the amino acid sequence is DFLAAT, and is shown as SEQ ID NO. 3.
4. 4. Use of a retinaldehyde dehydrogenase-activating peptide according to any of claims 1-3 as or in the preparation of a retinaldehyde dehydrogenase activator.
5. 5. Use of a retinoid dehydrogenase-activating peptide according to any one of claims 1-3 as or in the preparation of a food or medicament for ameliorating intestinal side effects of radiotherapy.

Description

Retinoic aldehyde dehydrogenase activating peptide and application thereof in prevention and treatment of radiotherapy intestinal side reaction Technical Field The invention relates to a retinaldehyde dehydrogenase activated peptide and application thereof in prevention and treatment of radiotherapy intestinal side reaction, belonging to the technical field of bioactive peptides. Background The radioactive intestinal injury (Radiation Intestinal Injury, RII) is a serious side effect caused by pelvic/abdominal tumor radiotherapy, and clinically presents diarrhea, abdominal pain, hematochezia and the like, 90% of patients have gastrointestinal side effect symptoms, and the quality of life of the patients is obviously affected. The existing therapies are mainly symptomatic treatment and lack targeted repair means. In the prevention and treatment system of radiotherapy intestinal side effects, retinoic acid (Retinoic Acid, RA) -mediated intestinal mucosa immune repair plays a key role. The biosynthesis process of RA is highly dependent on the catalytic action of the enzyme retinoid dehydrogenase (ALDH 1A 1). When ALDH1A1 is low in activity, RA synthesis is insufficient, so that repair procedures such as intestinal mucosa immune cell differentiation, tight junction protein expression, flora steady state regulation and the like cannot be effectively started, and the primary mechanism that radiotherapy intestinal side reaction is difficult to realize autonomous repair is adopted. Based on the pathological logic, the synthesis capacity of the ALDH1A1 activity for recovering endogenous RA is targeted and activated, and the ALDH1A1 activity has become a therapeutic target with great potential for preventing and treating intestinal side effects of radiotherapy. In recent years, the development of molecular docking virtual screening technology provides a new path for efficient discovery of targeted peptides. Through computer simulation of ligand-receptor interaction, large-scale peptide library screening and mechanism analysis can be completed within a few weeks, and research and development efficiency is remarkably improved. Therefore, the invention identifies and screens 3 retinoid dehydrogenase activated peptides from antarctic krill protein peptides as marine raw materials based on a molecular docking virtual screening technology, and combines animal experiments to determine the application value of the retinoid dehydrogenase activated peptides in RII control. Disclosure of Invention According to the invention, 3 kinds of retinoid dehydrogenase activated peptides with brand new structures are successfully obtained from a self-built ocean raw material euphausia superba protein peptide database through virtual screening by utilizing a molecular simulation technology, the binding action sites of peptide fragments and retinoid dehydrogenase are further analyzed, the efficacy of the retinoid dehydrogenase is verified through animal experiments, and a brand new solution is provided for RII prevention and treatment. The invention is realized by the following technical scheme: the amino acid sequences of the following 3 kinds are respectively: FEEF as shown in SEQ ID NO. 1; FGREE as shown in SEQ ID NO. 2; DFLAAT as shown in SEQ ID NO. 3. The 3 euphausia superba active peptides are applied to serving as or preparing a retinoid dehydrogenase activator and serving as or preparing a food or medicine for improving radiotherapy intestinal side effects. The three active peptides of the invention are identified and screened from antarctic krill protein peptide by utilizing high-resolution mass spectrum and molecular docking virtual screening technology, and the process is as follows: (1) And directly detecting peptide fragments existing in the sample through high-resolution mass spectrum, identifying peptide fragment sequences of euphausia superba protein peptides, and establishing a polypeptide database. (2) The retinoid dehydrogenase (ALDH 1A 1) was docked with oligopeptides of the peptide library. (3) Animal experiments are adopted to verify the influence of the screened active peptide on the side effect of radiotherapy intestinal tract. By using the method, 3 potential ocean source ALDH1A1 activation peptides are screened out, and animal experiments are adopted to verify the influence of the three euphausia superba active peptides on the radiotherapy intestinal side reaction of the mice. The results show that 3 oligopeptides show obvious improvement effects, and the oligopeptides have potential as functional products for improving the side effects of the radiotherapy intestinal tract and can be used for preparing foods or medicines with the effect of improving the side effects of the radiotherapy intestinal tract. The invention innovates the ALDH1A1 activated peptide screening method with complicated steps in the traditional technology, and develops the virtual screening of the marine active peptide from the protein complete s